Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy

Ther Drug Monit. 2000 Aug;22(4):383-5. doi: 10.1097/00007691-200008000-00003.

Abstract

The authors report a possible interaction between ketobemidone and busulfan during myeloablative treatment of a patient with acute myeloid leukemia. At the time of admission, the patient was receiving ketobemidone 1,000 mg/d as analgesic for a rectal fissure. The patient started conditioning prior to bone marrow transplantation with busulfan (1 mg/kg x 4 for 4 days). High busulfan plasma concentrations were observed after the first dose and the next doses were reduced to 0.7 mg/kg. The kinetics of both drugs revealed that an increase in ketobemidone concentration was followed by an increase in busulfan levels. Substituting ketobemidone with morphine resulted in a decrease in busulfan concentration despite increasing the dose once more to 1 mg/kg.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analgesics, Opioid / pharmacology*
  • Antineoplastic Agents, Alkylating / pharmacokinetics*
  • Busulfan / pharmacokinetics*
  • Drug Interactions
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Meperidine / analogs & derivatives*
  • Meperidine / pharmacology

Substances

  • Analgesics, Opioid
  • Antineoplastic Agents, Alkylating
  • Meperidine
  • Busulfan
  • ketobemidone